MDR is being priced as MedAdvisor and not MedAdvisor with Adheris.
Anyone buying before the June quarter results is extremely brave.
There's a number of announcements to get through that might steady the ship:
- Replacement CEO. They are targeting a US based Exec.
- What calibre resource will they get to manage an ASX listed healthcare stock?
- Final earn-out to Syneos in September.
- How will this be funded? Cash, CR, PFG?
Better numbers in June is needed, else they will require a number of quarters to regain trust.
- Any and I mean any price sensitive news that confirms an extension to or new revenue stream.
- It's all well and good to simply publish quarterlies, if you're meeting your revenue targets.
Add to My Watchlist
What is My Watchlist?
